Tuszynski et al. conducted another phase I clinical trial in which 10 patients with early AD underwent NGF gene therapy using ex vivo or in vivo gene transfer, and post-mortem analysis on 10 subjects with survival times ranging from 1 to 10 years post-treatment was performed. This evidence concerns the gene NGF and Alzheimer disease.